seems to be one of the major prognosis factors of this disease, with progression-free and overall survivals significantly higher for patients with pathologic complete Inflammatory breast cancer still has a poor prognosis despite improvements related to the introduction of neoresponse to chemotherapy than for patients with residual disease. [8][9][10] One way of increasing survival for patients with adjuvant chemotherapy. The purpose of this study was to evaluate pathologic response rate and outcome of inflammatory breast cancer could be to introduce more efficient induction chemotherapy. patients receiving high-dose chemotherapy with haematopoietic stem cell support for IBC. Seventeen consecuDose and dose intensity have been shown to have a major impact on chemotherapy results, in both experimental modtive patients with IBC received an association of mitoxantrone (36 mg/m 2 ), cyclophosphamide (120 mg/kg), els, 11,12 and metastatic or non-metastatic breast cancer. encouraging results in response rate, progression-free and overall survival.
13,14
On this basis, high-dose chemotherapy with haematopoietic melphalan (140 mg/m 2 ), with stem cell transplantation (SCT) following four to five cycles of cyclophosphamide stem cell transplantation has been widely tested in breast cancer, either in metastatic or non-metastatic disease, with (1000 mg/m 2 ), doxorubicin (75 mg/m 2 ) and 5FU (500 mg/m 2 ). Mastectomy was performed a median of 2 encouraging results in response rate, progression-free and overall survival. [15] [16] [17] months (range 1.5-45) after high-dose chemotherapy and was followed by radiotherapy. Macroscopic and The use of this approach could be important in improving results of treatment in inflammatory breast cancer. As microscopic pathologic complete response rates were respectively 56 and 39%. With a median follow-up of pathologic response rate has been shown to be predictive of evolution in this pathology, this criterion can be used as 36 months (range 17-52) 10 patients remain alive free of disease and seven patients have relapsed. Two relapses a first evaluation for new strategies in this disease. The purpose of this study was to evaluate the impact of highoccurred in the group of patients with pathologic CR and five in the group with residual tumour. These dose chemotherapy with haematopoietic stem cell transplantation on pathologic response and outcome in results show that high-dose chemotherapy (HDC) with alkylating agents followed by SCT allows a very high inflammatory breast carcinoma. tumour eradication in inflammatory breast cancer, suggesting a possible global benefit in progression-free survival and survival which remains to be demonstrated Patients and methods prospectively. Keywords: inflammatory breast cancer; high-dose Patient selection chemotherapy; stem cell transplantation; pathologic response Consecutive patients with inflammatory breast cancer were included in this study. Inflammatory breast cancer was clinically defined according to the Institut Gustave Roussy criteria: 1 PEV2 denotes inflammation (erythema and/or Clinically defined inflammatory breast cancer is uncomoedema) localized to the tumour site, and PEV3 denotes mon, occurring in only about 2-4% of all breast cancer.
1,2 generalized breast inflammation. Initial skin biopsy was When treated with a combination of surgery and radioobtained as often as possible, but the absence of dermal therapy, the 5 year survival rate has generally been less lymphatic carcinomatosis was not an exclusion criterion. than 15%.
3 Introduction of neoadjuvant chemotherapy has Before entering the study, patients had to give oral consent improved results leading to 5 year survival rates of between for the treatment, including mastectomy. Other patient 30 and 50% and there is currently no doubt that treatment eligibility requirements included: women aged at least 18 of inflammatory breast cancer must include neoadjuvant years, non-menopausal, with WHO performance status 0, 1 chemotherapy. [4] [5] [6] [7] Moreover, response to chemotherapy or 2, neutrophil count superior to 1. histologic parameters were evaluated. Immunohistochemisafter chemotherapy and during G-CSF stimulation, as soon try was performed, as described 20 using antibodies against as blood CD34
+ cells reached 20/l. A minimum of p53 (D01; Immunotech, France) ERBB2 (Neu AB3; Onco-3 ϫ 10 6 CD34 + cells/kg were collected. Leukaphereses gene Sciences, USA), oestrogen receptor (1 D5; Immunowere performed between the 2nd and 3rd cycle or between tech, Marseille, France) and progesterone receptor (1 A 6 ; the 3rd and 4th cycle. Procedures for collection and CD34 + Novocastra, Newcastle, UK). Mastectomy specimens were evaluation have been previously published. 18 No attempt thoroughly examined with sections taken from each quadwas made to purge haematopoietic stem cells of possible rant, from the nipple aerolar complex and areas suspected tumour.
of having tumour involvement. After chemotherapy, pathoHigh-dose chemotherapy was administered as soon as logic response was assessed first by macroscopy using possible after the last cycle of conventional chemotherapy.
Feldman's definition: 8 a gross pathologic complete It consisted of a combination of mitoxantrone 12 mg/m 2 response was defined as the absence of any macroscopic day from day Ϫ7 to day Ϫ5, cyclophosphamide 60 evidence of tumour upon gross inspection regardless by the mg/kg/day from day Ϫ3 to day Ϫ2 and melphalan 140 subsequent findings of microscopy. The alternative was mg/m 2 day 1. Mitoxantrone was given as a 15 min intraresidual tumour on gross examination which was classified venous injection, cyclophosphamide as a 1 h intravenous as failure. infusion and melphalan as an intravenous bolus. Thawed
Microscopic response was also assessed as described, 21 stem cells were given on day 0. 19 Patients were managed in a stem cell transplantation unit, in a single room with and consisted of: grade I: disappearance of all tumour both reverse isolation. Intravenous antibiotics were started as on macroscopic and microscopic examination; grade II: soon as patients became febrile (axillary temperature presence of in situ carcinoma and/or presence of necrotic Ͼ38°C). Packed red cells were transfused when the haemoand scanty vascular emboli; grade III: presence of invasive globin dropped to under 8 g/dl and platelets for haemorcarcinoma with stromal alterations; and grade IV: few or rhage or when platelets dropped to under 20 ϫ 10 9 /l. All no alterations of the tumoural component. blood products were irradiated at 25 Gy.
Modified radical mastectomy with axillary lymph node dissection (if not initially done) was performed after highdose chemotherapy, as soon as patients had sufficient
Statistical analysis haematological recovery. After surgery, all patients were treated with mega voltage radiation therapy using tangential Survival and progression-free survival were estimated using fields directed at the chest wall. Patients were treated with the Kaplan-Meier method 22 and curves were compared a total dose of 46 Gy to the chest wall delivered with 4 with the log-rank test. 23 Differences were considered sigMeV photons, then a 10 Gy boost was given via smaller nificant when P Ͻ 0.05. Progression-free survival was tangential fields, or electron beam with an energy of defined as the time elapsed between date of diagnosis and between 6 and 13 MeV. Regional nodal irradiation was perdate of first relapse, wherever this relapse might be. Overall formed on all patients. The supraclavicular fossa received survival was the period between time of diagnosis and time 46 Gy, the axillary region 50 Gy and the internal mammary of last status report, whether the patient was alive or dead, nodes 46 Gy with 4 MeV photons mixed with the electrons.
whatever the cause of death. Percentage differentials were After completion of local treatment, all patients received tested by application of the 2 test. tamoxifen 20 mg/day for 3 years, regardless of hormone receptors.
Results
response after intensive chemotherapy, such as: histologic grade, expression of oestrogen and/or progesterone receptors, expression of P53 or ERBB2 proteins. Of the three Patient characteristics and therapy axillary dissections, two had no tumour (neither had any Seventeen pre-menopausal women were entered in the invasive tumour in the breast specimen) but in the third study. Their median age was 46 years (range 24-54). All specimen residual tumour was found (persistent invasive had inflammatory breast cancer, one of them having bilattumour in the breast specimen). eral breast cancer. Two of these 17 patients had a single area of increased uptake of radionuclide on bone scan. All Outcome the patients received high-doses of FAC (10 patients four cycles and seven patients five cycles). All received full Overall, with a median follow-up of 36 months (range 17-doses of this chemotherapy regimen within the scheduled 52), seven patients had further evolution of disease (initially time. High-dose chemotherapy and autologous stem cell local in three and initial distant metastasis in four) which transplantation were carried out in a median of 5 months occurred a median of 12 months (range 3-38) post autolog-(range 4-7) after diagnosis.
ous stem cell transplantation. One of the two patients with Toxicity post high-dose chemotherapy and autologous initial increased uptake on bone scan relapsed (pathologic stem cell transplantation was mainly haematological: after failure in the breast) and the other did not (pathologic comtransplantation, absolute neutrophil count reached plete response in the breast). At the present time 13 patients 0.5 × 10 9 /l a median of 11 days (range 8-17), and platelets are alive, 10 without evidence of disease: 3 year projected reached 25 × 10 9 /l a median of 11 days (range 8-33). The disease-free survival and survival are respectively 66 (95% median duration of hospitalization for high-dose chemo-CI: 44-88%) and 68 (95% CI: 40-89%) (Figure 1 ). therapy and stem cell transplantation was 25 days (range Pathologic response was clearly predictive of final out-18-38). Nine out of the 17 patients experienced bacteraecome since only two out of 10 patients with macroscopic mia and patients received a median of 11 days (range 8-pathologic response relapsed, compared to five out of seven 31) of intravenous antibiotics, four (range 0-8) packed red patients with pathologic residual tumour (P Ͻ 0.02 by log cells and three (range 2-19) of platelet transfusion. No rank test) (Figure 2 ). patient died from the procedure.
Surgery was performed a median of 2 months (range 1.5-4.5) after high-dose chemotherapy and a median of 7 Discussion months (range 6-10) after diagnosis. Surgery consisted of modified radical mastectomy for 16 patients and bilateral Primary chemotherapy is currently included as a major part radical mastectomy for the last patient, hence giving 18 of the treatment of inflammatory and locally advanced samples. Three of these patients had additional axillary breast cancer. Local treatment alone or followed by adjudissection, which was not performed at diagnosis.
vant chemotherapy results in a high rate of local and general failure. Moreover, a clear correlation has already been established between pathologic response to primary chemoClinical and pathologic response (Table 1) therapy and outcome. In our study, an attempt was made to increase pathologic Before high-dose chemotherapy, one patient had stable disease (persistence of inflammatory signs) and all the others response rate by using high-dose chemotherapy with autologous haematopoietic stem cell transplantation after conhad evidence of clinical response to induction chemotherapy.
ventional but intensified induction chemotherapy. We report a 56% pathologic response rate in 17 patients using At the time of mastectomy, all 17 patients had evidence of clinical response: nine tumours were considered as clinimacroscopic evaluation and a 39% major response rate using microscopic evaluation. Despite the relatively small cal complete responses and nine as clinical partial responses.
number of patients in our study, these data strongly suggest that intensification of chemotherapy, allowed by the use of By macroscopic evaluation, of the 18, no evidence of residual gross tumour was found in 10 specimens (56% autologous stem cell transplantation, is associated with a high pathologic response rate when compared with results pathologic macroscopic complete response). By microscopic evaluation, seven out of 18 mastectomy specimens achieved by standard or less intensified chemotherapy. After conventional chemotherapy, microscopic complete (39%) showed no invasive tumour and were described as grades I and II. In 11 specimens (61%) residual invasive response or 'major response' ranges between 0 and 25% in series of patients where pathologic criteria are precisely tumour was clearly documented (grades III and IV). Major cytological and histological changes were observed in the defined and comparable to our study (Table 2 ). In the study by Sataloff et al, 10 the authors report higher pathologic specimen analyzed post-intensive chemotherapy. In most patients, even normal breast tissue was frequently altered response rates in 36 patients treated by FAC or CMF (14 out of 36). However, these very good results are difficult by chemotherapy: lobular atrophy and cytoplasmic vacuolization were the most commonly observed features; freto compare with the criteria used in our study and in other published series, since pathologic response is only defined quent stromal alterations were also observed, consisting of fibrous involution, increased elastosis and areas of necrosis.
as 'total or near total therapeutic effect'. Two of the best results obtained with 'conventional' chemotherapy were In this set of patients, we did not identify any biological marker which could possibly be predictive of pathologic obtained using high-dose intensity conventional chemo- therapy 27 or intra-arterial chemotherapy 25 suggesting a probable dose-response relationship for achieving major responses in the subgroup of patients with inflammatory breast cancer.
The existence of a dose-response relationship in advanced and/or metastatic breast cancer is documented with numerous chemotherapeutic agents and in various studies. However, in our study, despite a major increase in dose intensification allowed by the use of stem cell transplantation, given even early in the course of disease, it is clear that residual tumour cells are present: 61% of our patients still have residual invasive tumour cells on local specimens. This pathologic resistance is furthermore associated, as reported in other studies, with an adverse prognosis. This relative local chemoresistance can be due to the combination chemotherapy used in our set of patients associating high-doses of melphalan, cyclophosphamide and mitoxantrone. This chemotherapy is clearly suboptimal for these patients: however, in other measurable situations such as metastatic breast cancer, several other combinations of alkylating agents have been tested but it is difficult, to date, to clearly identify the optimum drug combination in breast cancer. 29 No predictive factor for response was found in our study, and in particular, ERBB2 was not predictive of response to high-dose chemotherapy and autologous stem cell transplantation as has been previously published for patients treated with dose escalation of standard chemotherapy. 30 Only two patients in our study had positive immunostaining for ERBB2; one was in pathologic complete response, one in pathologic failure. A larger series could confirm the pre- response, patient selection with ERBB2-positive immuno-
